The effect of acebutolol on cardiac arrhythmias in patients with chronic coronary artery disease.
The effect of the beta-blocking drug acebutolol on the severity of cardiac arrhythmias and the incidence of exercise-induced arrhythmias was studied in 15 patients with chronic coronary artery disease using ambulatory Holter monitoring and bicycle ergometry. We found a significantly lower grading of arrhythmias both on long-term ECGs and during and after exercise. Furthermore, there was a significant decrease in the incidence of VPBs during and after exercise (18.15 +/- 7.7 on placebo vs. 3.46 +/- 1.7 on acebutolol). It is concluded that acebutolol favorably influences the incidence and severity of ventricular arrhythmias in patients with chronic coronary artery disease.
D000070:Acebutolol / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy*; D003327:Coronary Disease / Q000150:complications*; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D000070:Acebutolol